Compare ANIX & SHIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIX | SHIM |
|---|---|---|
| Founded | 1982 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 128.6M |
| IPO Year | 2013 | 2023 |
| Metric | ANIX | SHIM |
|---|---|---|
| Price | $2.68 | $2.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $9.75 | $7.00 |
| AVG Volume (30 Days) | ★ 306.6K | 120.3K |
| Earning Date | 09-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 81.95 |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $492,844,000.00 |
| Revenue This Year | N/A | $1.41 |
| Revenue Next Year | N/A | $20.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.63 |
| 52 Week Low | $2.32 | $1.95 |
| 52 Week High | $5.46 | $6.76 |
| Indicator | ANIX | SHIM |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 29.67 |
| Support Level | $2.62 | $2.45 |
| Resistance Level | $3.09 | $4.09 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 7.17 | 5.95 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.